Search Articles
LOS ANGELES – Obagi pharmaceuticals is selling itself too cheaply to Valeant Pharmaceuticals, for $19.75 a share or $360 million, shareholders claim in Superior Court.
Categories /
Uncategorized
Subscribe to our free newsletters
Our weekly newsletter Closing Arguments offers the latest about ongoing trials, major litigation and rulings in courthouses around the U.S. and the world, while the monthly Under the Lights dishes the legal dirt from Hollywood, sports, Big Tech and the arts.